Evofem Biosciences, Inc.

OTCPK:EVFM Stock Report

Market Cap: US$1.0m

Evofem Biosciences Management

Management criteria checks 1/4

Evofem Biosciences' CEO is Saundra Pelletier, appointed in Jan 2018, has a tenure of 6.92 years. total yearly compensation is $1.52M, comprised of 36.9% salary and 63.1% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth $14.44. The average tenure of the management team and the board of directors is 1.7 years and 6.9 years respectively.

Key information

Saundra Pelletier

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage36.9%
CEO tenure6.9yrs
CEO ownership0.001%
Management average tenure1.7yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

Evofem partners with a360 Media to support Phexxi prescription growth

Jul 21

Evofem announces peer-reviewed publication on birth control method

Jul 12

Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier

Jul 06

Evofem announces U.S. patent win for birth control method

Jun 30

Evofem: ACA Coverage Of Phexxi Is A Game Changer

Jan 18

CEO Compensation Analysis

How has Saundra Pelletier's remuneration changed compared to Evofem Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$11m

Jun 30 2024n/an/a

US$57m

Mar 31 2024n/an/a

US$47m

Dec 31 2023US$2mUS$560k

US$50m

Sep 30 2023n/an/a

US$44m

Jun 30 2023n/an/a

US$67m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$1mUS$812k

-US$78m

Sep 30 2022n/an/a

-US$119m

Jun 30 2022n/an/a

-US$283m

Mar 31 2022n/an/a

-US$192m

Dec 31 2021US$3mUS$812k

-US$206m

Sep 30 2021n/an/a

-US$194m

Jun 30 2021n/an/a

-US$150m

Mar 31 2021n/an/a

-US$169m

Dec 31 2020US$4mUS$781k

-US$142m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$98m

Mar 31 2020n/an/a

-US$81m

Dec 31 2019US$3mUS$847k

-US$80m

Sep 30 2019n/an/a

-US$82m

Jun 30 2019n/an/a

-US$87m

Mar 31 2019n/an/a

-US$75m

Dec 31 2018US$8mUS$738k

-US$126m

Sep 30 2018n/an/a

-US$131m

Jun 30 2018n/an/a

-US$188m

Mar 31 2018n/an/a

-US$172m

Dec 31 2017US$2mUS$731k

-US$109m

Compensation vs Market: Saundra's total compensation ($USD1.52M) is above average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: Saundra's compensation has increased whilst the company is unprofitable.

CEO

Saundra Pelletier (54 yo)

6.9yrs

Tenure

US$1,520,455

Compensation

Ms. Saundra Pelletier has been Chief Executive Officer and President of Evofem Biosciences, Inc. since January 17, 2018. She is an Independent Director at Windtree Therapeutics, Inc. since August 13, 2024....

Leadership Team

NamePositionTenureCompensationOwnership
Saundra Pelletier
Interim Chair6.9yrsUS$1.52m0.0014%
$ 14.4
Ivy Zhang
CFO & Secretary1.7yrsUS$438.85k0.000090%
$ 0.9
Amy Raskopf
Chief Business Development Officer & Senior VP of Investor Relationsno datano datano data
Ellen Thomas
Chief of Staffno datano datano data
Kathy Gallo-Doyle
Senior Vice President of Commercial Operationsless than a yearno datano data

1.7yrs

Average Tenure

Experienced Management: EVFM's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Saundra Pelletier
Interim Chair6.9yrsUS$1.52m0.0014%
$ 14.4
Colin Rutherford
Independent Director6.9yrsUS$70.00k0%
$ 0
Lisa Rarick
Independent Director4.8yrsUS$55.00k0%
$ 0
Kim Kamdar
Independent Director6.9yrsUS$77.62k0.000010%
$ 0.1
Tony O'Brien
Independent Director6.9yrsUS$75.00k0%
$ 0

6.9yrs

Average Tenure

61yo

Average Age

Experienced Board: EVFM's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 05:54
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Evofem Biosciences, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John TannerCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.
I-Eh JenLaidlaw & Company (UK) Ltd